Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Event Contracts
New
Predict price moves and seize opportunities
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
0 Fee
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
JP Stocks
Top Japanese stocks, all in one place
Stock Futures
High leverage, 24/7 trading
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD Flexible US Treasury
3.8%
Earn reliable returns from treasury-backed RWAs
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
9.99%
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
Moderna's Stormy Rise 🧐
Moderna (mRNA) stormed the week, closing at $145.04 on Friday with an 8.77% jump. A 130% weekly increase, a 143% monthly gain, and a massive 446% year-on-year performance have made the company one of the most talked-about stocks in the S&P 500. But is this rally a harbinger of the revolution promised by mRNA technology, or a bubble detached from fundamental indicators?
Historic Milestone with mCOMBRIAX
The most significant development that propelled Moderna to this point was the European Commission's marketing approval for mCOMBRIAX (mRNA-1083) on April 21, 2026. This became the world's first mRNA combination vaccine to combine influenza and COVID-19 in a single vaccine. The vaccine, approved for adults aged 50 and over, is valid in EU countries, Iceland, Liechtenstein, and Norway.
A Phase 3 study involving approximately 8,000 adults showed that mRNA-1083 generated a statistically higher immune response against SARS-CoV-2 and three influenza strains (A/H1N1, A/H3N2, B/Victoria) compared to licensed vaccines administered separately. This was Moderna's fourth approved product.
Financial Statement
Moderna's balance sheet shows that this success has not yet been reflected in profit. The P/E ratio is negative (-18.186), and its market value is $57.9 billion. In the last quarter (Q2 2026), revenue was $143 million, while net loss reached $782 million. This reflects the company's research and development expenses and the cost of financing clinical trials.
However, analysts' expectations are optimistic. The average revenue forecast for 2026 is $2.11 billion, and for 2027 it is $2.46 billion. Loss is also expected to narrow: the forecast of -$8.58 per share for 2026 will decrease to -$4.86 in 2027.
Cancer Vaccines and More
mCOMBRIAX is just the beginning. Moderna's pipeline spans a wide range, from cancer vaccines to treatments for rare diseases. One of the most notable developments is the personalized cancer vaccine (mRNA-4157) developed in conjunction with Merck, and vaccines targeting the KRAS variant. Five years of data from a Phase 3 study in melanoma patients have shown promising results.
Also, ahead of the earnings report scheduled for November, the FDA approval process for the company's flu vaccine mRNA-1010 and developments in its CMV (cytomegalovirus) vaccine are being closely watched.
🤔 Expensive or Worth It?
Moderna's price is trading near its highest level in 52 weeks and above its 200-day simple moving average. The 1-year price forecast range from $25 to $170 across 19 analysts. This wide range reflects the uncertainty surrounding the company's future.
Moderna represents the tension between the revolution promised by mRNA technology and current profitability. The commercial success of mCOMBRIAX and data from cancer vaccines will determine the stock's future trajectory.
To avoid missing out on this exciting transformation story and market opportunities, open an investment account now and add mRNA to your watchlist!
DYOR 🔎 NFA ✔️
#GateStockInsightsChallenge $MRNA
Two Candidates, One Target: New Hope in the Fight Against Cancer
SLS has two main weapons. First, its peptide immunotherapy galinpepimut-S (GPS). This targets the Wilms tumor 1 antigen and is currently in Phase 3 REGAL trials with patients with acute myeloid leukemia (AML). Second, its CDK9 inhibitor SLS009 (tambiciclib). This is in Phase 2 trials with newly diagnosed AML patients.
The company has no commercial revenue yet. Net loss in the second quarter of 2026 increased to $9.6 million, resulting in a loss per share of $0.05. However, research and development spending rose to $6.3 million with the acceleration of the GPS and SLS009 studies. Cash position appears strong at $138.3 million.
REGAL Study: News Awaiting Alert
GPS's REGAL study targets AML patients in their second full remission. A threshold of 80 events (patient deaths) was set for the final analysis of the study. In May, this number reached 78, and the company announced that analysis would begin upon the occurrence of the 80th event. Management is currently blind to the results and stated that an announcement will be made when an event occurs, followed by a period of silence until the final results are released.
Industry Trend: The Moderna-Merck Effect
One of the biggest catalysts for the recent movement in SLS was the positive results from Moderna and Merck’s Phase 3 melanoma trial of their individualized mRNA cancer vaccine. Maxim Group analysts called this success a “victory for cancer vaccines” and argued that the rise in Moderna could see similar interest if SLS’s GPS study is successful. Analysts assigned a “BUY” rating and a $30 target price for SLS.
The overall market outlook for SLS is positive. Alliance Global Partners raised its target price from $25 to $35 and maintained its “BUY” rating. The 12-month average target price is $32.50, representing over 100% upside potential at the current price.
However, not all analysts agree. Simply Wall St’s valuation checks placed SLS in the “expensive” category with a score of 0 out of 6. The price-to-book ratio of 19.7x is significantly above the biotechnology sector average of 2.5x and its peers' 14.1x. This indicates that the market is premiuming the company's future potential over its current assets.
Expectations and Risks
The following factors will be decisive for SLS in the upcoming critical period:
• GPS Phase 3 REGAL results: Positive results could be a turning point for the company. • SLS009 Phase 2 data: Expected to be released in Q4 2026 for newly diagnosed AML patients. • Funding needs: Lack of revenue and increasing R&D expenditures keep the need for additional capital on the agenda.
SLS is a biotechnology story offering both high risk and high reward potential. Sectoral optimism in cancer vaccines and data from the REGAL study will determine the stock's fate. To closely follow this exciting journey and not miss opportunities, activate your investment account now and add SLS to your watchlist!
DYOR 🔎 NFA ✔️
#GateStockInsightsChallenge